Results 1 to 10 of about 10,630 (243)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts [PDF]

Allergy, Asthma & Clinical Immunology, 2021
Background Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti-interleukin-5 receptor alpha (IL-5Rα) antibody targeting the IL-5 receptor on
Arian Ghassemian, Jane Jiyoon Park, Michael W. Tsoulis, Harold Kim   +3 more
doaj   +2 more sources

Potential impact of mepolizumab in stepping down anti-osteporotic treatment in corticosteroid-dependent asthma

Frontiers in Pharmacology, 2023
Oral corticosteroids (OCS) are commonly used for the acute management of severe asthma exacerbations or as maintenance therapy; however, chronic use is associated with significant toxicities, e.g., osteoporosis. In the REal worlD Effectiveness and Safety
Christian Domingo, Christian Domingo, Ana Sogo, Ana Sogo, Enrique Casado, Eva Martínez-Moragón, Marina Blanco-Aparicio, Teresa Carrillo, Teresa Carrillo, David Bañas-Conejero, María-Guadalupe Sánchez-Herrero   +10 more
doaj   +2 more sources

Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence [PDF]

Frontiers in Immunology
Hypereosinophilic syndrome (HES) is a rare condition characterized by elevated eosinophil levels and related symptoms of eosinophil-mediated organ damage. We reviewed the effectiveness and safety of mepolizumab for the treatment of HES.
Elvira Mora, María Laura Fox, María Laura Fox, Angelina Lemes, Beatriz Velasco, Jesús María Hernández-Rivas, Jesús María Hernández-Rivas   +6 more
doaj   +2 more sources

Protocol for an open labelled observational study in children & adolescents with severe asthma with an eosinophilic phenotype treated with mepolizumab (CASAM). [PDF]

PLoS One
Gupta A, de Mir Messa I, Valverde-Molina J, Murray CS, Moral L, Torres Borrego J, Pike K, Díaz-Izquierdo A, Martínez-Cañavate A, Nagakumar P, Cook J, Gupta L, CASAM Group.   +12 more
europepmc   +2 more sources

More Than Five Years of Sustained Remission With Mepolizumab in Adolescent-Onset Eosinophilic Granulomatosis With Polyangiitis: A Case Report. [PDF]

Cureus
Araya T, Kita T, Iwabuchi T, Higashi T, Hara R.   +4 more
europepmc   +3 more sources

Mepolizumab for the management of chronic rhinosinusitis with nasal polyps across the United States: A retrospective study [PDF]

Journal of Allergy and Clinical Immunology: Global
Background: Retrospective data are limited on the effectiveness of mepolizumab treatment that is reflective of real-world practice in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Juan Carlos Cardet, MD, MPH, Jared Silver, MD, Martin Maldonado-Puebla, MD, François Laliberté, MA, Chi Gao, PhD, Ramya Ramasubramanian, PhD, Annalise Hilts, BA, Kaixin Zhang, MSc, Jeremiah Hwee, PhD, Waseem Ahmed, MBA, Amy G. Edgecomb, PharmD, MPH   +10 more
doaj   +2 more sources

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system

Frontiers in Pharmacology, 2023
Background: Mepolizumab has been approved by the FDA for add-on maintenance treatment of severe asthma with an eosinophilic phenotype. Real-world studies on mepolizumab-associated adverse events are limited. The present study aimed to explore mepolizumab-
Huqun Li, Chongshu Wang, Aiping Deng, Cuilian Guo   +3 more
doaj   +1 more source

Mepolizumab [PDF]

Hospital Pharmacy, 2016
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Cada, Dennis J, Bindler, Ross J, Baker, Danial E   +2 more
openaire   +3 more sources

Severe asthma remaining well‐controlled after mepolizumab discontinuation: A case report and literature review

Respirology Case Reports, 2023
Mepolizumab, a humanized anti‐IL‐5 monoclonal antibody used for severe asthma, results in a reduced rate of asthma exacerbation, improved lung function, reduced oral corticosteroid use, and improved quality of life.
Takahiro Matsuyama, Yuya Tomioka, Hiromi Matsuyama, Yusuke Kamenohara, Kengo Tanigawa, Yoichi Dotake, Yoko Hagihara, Koichi Takagi, Kentaro Machida, Hiromasa Inoue   +9 more
doaj   +1 more source

Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis

Allergy, Asthma & Clinical Immunology, 2023
Background The mainstay of treatment for eosinophilic granulomatosis with polyangiitis (EGPA) is systemic corticosteroid therapy; some patients also receive intravenous immunoglobulins, other immunosuppressive agents, and biologics.
Nami Masumoto, Chiyako Oshikata, Ryo Nakadegawa, Yuto Motobayashi, Reeko Osada, Saki Manabe, Takeshi Kaneko, Naomi Tsurikisawa   +7 more
doaj   +1 more source